Letter to the editor

1. Rogers NM, Eng HS, Yu R, et al. Desensitization for renal
transplantation: depletion of donor-specific anti-HLA
antibodies, preservation of memory antibodies, and clinical
risks. Transplant Int 2011; 24: 21.
2. Cambridge G, Leandro MJ, Teodorescu M, et al. B cell
depletion therapy in systemic lupus erythematosus. Arthritis
Rheum 2006; 54: 3612.
3. Pondrom S. The AJT Report: news and issues that affect
organ and tissue transplantation. Am J Transplant 2010;
10: 2.
4. Ramos EJ, Pollinger HS, Stegall MD, Gloor JM, Dogan A,
Grande JP. The effect of desensitization protocols on
human splenic B-cell populations in vivo. Am J Transplant
2007; 7: 402.
5. Warren DS, Montgomery RA. Incompatible kidney transplantation:
lessons from a decade of desensitization and
paired kidney exchange. Immunol Res 2010; 47: 257.
6. Pohl MA, Lan SP, Berl T. Plasmapheresis does not increase
the risk for infection in immunosuppressed patients with
severe lupus nephritis. Ann Intern Med 1991; 114: 924.
7. Akalin E, Dinavahi R, Friedlander R, et al. Addition of
plasmapheresis decreases the incidence of acute antibodymediated
rejection in sensitized patients with strong
donor-specific antibodies. Clin J Am Soc Nephrol 2008; 3:
1160.
8. Grim SA, Pham T, Thielke J, et al. Infectious complications
associated with the use of rituximab for ABO-incompatible
and positive cross-match renal transplant
recipients. Clin Transplant 2007; 21: 628.
9. Kamar N, Milioto O, Puissant-Lubrano B, et al. Incidence
and predictive factors for infectious disease after rituximab
therapy in kidney-transplant patients. Am J Transplant
2010; 10: 89.
10. Kelesidis T, Daikos G, Boumpas D, Tsiodras S. Does
rituximab increase the incidence of infectious complications?
A narrative review. Int J Infect Dis 2011; 15: e2.
11. Gea-Banacloche JC. Rituximab-associated infections. Semin
Hematol 2010; 47: 187.